Lyme Vaccine Data at IDWeek Show Protection Was Measured Only After Four Doses Across Two Tick Seasons
Pfizer and Valneva's Lyme disease vaccine candidate, PF-07307405, showed 73.2% efficacy after four doses in a second tick season, missing its main statistical target. The trial involved nearly 10,000 participants, with 8,011 completing it. The vaccine is not yet approved, but regulatory reviews are underway in Europe and the U.S. according to the companies.
How this was made
The 30-second read
Why it matters
The data clarifies efficacy after the full four‑dose regimen but confirms the trial missed its primary statistical target, affecting regulatory expectations.
Market read
New trial details may adjust valuation expectations for both firms, especially regarding upcoming EMA and FDA decisions.
What to watch
Potential pricing, reimbursement, and multi‑dose schedule challenges could dampen adoption even if approved.
Background
The article reports detailed Phase 3 results for the investigational Lyme disease vaccine (PF‑07307405) from Pfizer and Valneva, presented at IDWeek.
Ticker impact
Pfizer presented new Phase 3 data showing 73.2% efficacy after the fourth dose, a fresh detail that could affect its vaccine pipeline valuation.
likely modest pressure as investors reassess the timeline and market potential of the Lyme vaccine.
The data is new but the vaccine remains unapproved; market reaction will depend on regulatory outcomes.
Market effects
May influence biotech investors focused on vaccine pipelines and infectious‑disease assets.
European biotech sentiment could shift with EMA review progress; US market impact limited to Pfizer exposure.
Limited to vaccine development community; not a broad market mover.
Counterpoint
The missed primary endpoint suggests the vaccine may never achieve commercial viability, limiting upside.
Key entities
- CompanyPfizer
US pharmaceutical giant developing the Lyme vaccine.
- CompanyValneva
European biotech partner in the vaccine development.
